NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms

Blood Rev. 2017 Mar;31(2):77-92. doi: 10.1016/j.blre.2016.10.001. Epub 2016 Oct 13.

Abstract

The NF-κB pathway, a critical regulator of apoptosis, plays a key role in many normal cellular functions. Genetic alterations and other mechanisms leading to constitutive activation of the NF-κB pathway contribute to cancer development, progression and therapy resistance by activation of downstream anti-apoptotic pathways, unfavorable microenvironment interactions, and gene dysregulation. Not surprisingly, given its importance to normal and cancer cell function, the NF-κB pathway has emerged as a target for therapy. In the review, we present the physiologic role of the NF-κB pathway and recent advances in better understanding of the pathologic roles of the NF-κB pathway in major types of lymphoid neoplasms. We also provide an update of clinical trials that use NF-κB pathway inhibitors. These trials are exploring the clinical efficiency of combining NF-κB pathway inhibitors with various agents that target diverse mechanisms of action with the goal being to optimize novel therapeutic opportunities for targeting oncogenic pathways to eradicate cancer cells.

Keywords: Apoptosis; B-cell lymphoma; EBV; MiRNA; NF-κB pathway; Tumor microenvironment.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor
  • Clinical Trials as Topic
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Leukemia, Lymphoid / diagnosis
  • Leukemia, Lymphoid / drug therapy*
  • Leukemia, Lymphoid / etiology
  • Leukemia, Lymphoid / metabolism*
  • Lymphoid Tissue / drug effects
  • Lymphoid Tissue / metabolism
  • Lymphoid Tissue / pathology
  • Lymphoma / diagnosis
  • Lymphoma / drug therapy*
  • Lymphoma / etiology
  • Lymphoma / metabolism*
  • Molecular Targeted Therapy*
  • Mutation
  • NF-kappa B / metabolism*
  • Signal Transduction / drug effects*
  • Treatment Outcome
  • Tumor Microenvironment

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • NF-kappa B